Mechanism of Action
Mitochondrial-Derived AMPK Activation
Mitochondrial-derived peptide that activates AMPK, improving glucose homeostasis and metabolic flexibility.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Compounds
1
Total studies
43
Human studies
2
FDA approved
0
Overview
MOTS-c is a 16-amino acid peptide encoded in the mitochondrial DNA. It acts as a hormone-like signal from mitochondria to the rest of the cell, activating AMP-activated protein kinase (AMPK) — the master regulator of cellular energy status. AMPK activation improves glucose uptake, enhances mitochondrial biogenesis, and promotes metabolic flexibility.
MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within mitochondrial DNA — a rare example of a peptide whose gene resides in the mitochondrial genome rather than the nucleus. It functions as a retrograde signal from mitochondria to the nucleus and peripheral tissues, activating AMPK and enhancing metabolic flexibility. Circulating MOTS-c declines with age and correlates with metabolic health in human cohort studies.
Receptor & signaling detail
MOTS-c's receptor mechanism is incompletely characterized. It appears to enter cells and engage metabolic sensing machinery directly, with AMPK activation as a proximal downstream event. A specific cell-surface receptor has not been definitively identified.
How it works
- 1Is encoded within mitochondrial DNA (12S rRNA region).
- 2Released into circulation under metabolic stress.
- 3Activates AMPK in skeletal muscle, liver, and adipose tissue.
- 4Enhances glucose uptake via GLUT4 translocation.
- 5Promotes mitochondrial biogenesis through PGC-1α.
Downstream clinical effects
- Improved insulin sensitivity
- Enhanced endurance and exercise capacity (preclinical)
- Mitochondrial biogenesis
- Potential longevity effects
Documented clinical implications
- Improved insulin sensitivity in preclinical models
- Enhanced endurance and exercise capacity in animal studies
- Mitochondrial biogenesis through AMPK/PGC-1α pathway
- Potential applications in age-related metabolic decline
Limitations & mechanism-driven side effects
- Human clinical trial data is in early stages (NCT05664867 and others)
- Not FDA approved for any indication
- Route of administration for therapeutic dosing in humans is still being optimized
- Long-term safety data is absent
Discovery & development
MOTS-c was discovered in 2015 by Lee and colleagues at USC, who identified functional small ORFs encoded within mitochondrial rRNA. The finding overturned assumptions about mitochondrial gene coding.
Peptides using this mechanism
Evidence status
Early-stage clinical trials (NCT05664867) are underway. Preclinical data is strong; human data is limited.
Frequently asked questions
What is MOTS-c?
MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA. It activates AMPK and functions as a metabolic signaling molecule between mitochondria and the rest of the cell.
Does MOTS-c improve exercise performance?
Animal studies show improved endurance and exercise capacity with MOTS-c supplementation. Human performance trials are early-stage and have not established this benefit in practice.
Is MOTS-c FDA approved?
No. MOTS-c is in early clinical development and not approved for any indication. It is not legal for non-research human use.
Does MOTS-c affect longevity?
Circulating MOTS-c declines with age and its pathway (AMPK activation, mitochondrial biogenesis) overlaps with longevity signaling. Direct human longevity data does not yet exist.
Relevant best-of guides
Best Peptides for Anti-Aging & Longevity
Peptides most investigated for cellular aging, telomere biology, and mitochondrial function — ranked by mechanism and evidence quality.
Best Peptides for Athletic Performance
Peptides associated with athletic performance contexts — ranked by evidence and WADA status.
Related articles
FDA Sets July 23–24 Meeting to Review BPC-157, TB-500, and 5 More Peptides for Compounding Access
Regulatory · 12 min
MOTS-c vs AOD-9604: Metabolic Peptides Compared
Comparison · 5 min
Best Peptides for Longevity: Anti-Aging Research 2026
Guide · 8 min
FDA Peptide Reclassification: March 2026 Status Update
Regulatory · 8 min
Related mechanism comparisons
NAD⁺ / Sirtuin & PARP Cofactor vs Mitochondrial-Derived AMPK Activation
Pathway, evidence, and compound comparison
Telomerase Activation vs Mitochondrial-Derived AMPK Activation
Pathway, evidence, and compound comparison
GLP-1 Receptor Agonism vs Mitochondrial-Derived AMPK Activation
Pathway, evidence, and compound comparison